Napo Pharmaceuticals announced that the European Patent Office and IP Australia, the Australian patent office, have each issued a new patent to Napo. The European patent covers methods for treating SBS, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug. The Australian patent covers methods of preventing, ameliorating and/or treating diarrhea associated with CDDs using a proanthocyanidin polymer composition such as crofelemer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health regains compliance with Nasdaq’s bid price requirement
- Jaguar Health Stockholders Approve Key Proposals at 2024 Meeting
- Jaguar Health to report Phase 3 OnTarget trial results on or before July 23
- Jaguar Health executes out-license dal with JV Magdalena Biosciences
- Jaguar Health anounces results of investigator-initiated trial of crofelemer